课题基金 / 基金详情

Integrative genomics to define osteocyte differentiation, regulation and function

Integrative genomics to define osteocyte differentiation, regulation and function
综合基因组学定义骨细胞分化、调节和功能
批准号:
8691297
负责人:
J WESLEY PIKE
金额:
$34.0万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-08 至 2019-07-31

项目摘要

项目成果

J WESLEY PIKE的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):骨细胞是成骨细胞来源的细胞,逐渐被埋入矿化的基质中,在那里它们的功能是调节骨骼的动态平衡;它们的重要性因其相对丰富和极长的寿命而凸显出来。令人惊讶的是,尽管已知骨细胞相对于其成骨前体表现出独特的基因表达模式,因此表现出独特的形式和功能,但对于协调其从成骨细胞过渡的分子机制或相关的表观基因组和调控决定因素知之甚少。此外,尽管Wnt信号被认为是成骨细胞和骨细胞活性的主要但不同的调节因子,但构成该途径细胞特异性活性的大多数基因靶点以及Tcf/Lef/b-catenin在这两种细胞中调节这些靶点的机制仍不清楚。因此,前两个目标的目标如下。目的1:确定在体外和体外成骨细胞向成骨细胞转化的表观基因组和调节组机制以及相关的全基因组水平的分子决定因素。目的:检测和比较Wnt信号通路对成骨细胞和成熟骨细胞特异性基因表达模式的影响,并探讨这些基因亚型在体外和体外受b-catenin直接调控和PTH和1,25(OH)2D3影响的分子机制。我们和其他人的初步数据显示,许多基因在骨细胞转变过程中上调,包括SOST、FGF23、Tnfsf11和Enpp1/3。然而,编码Wnt途径拮抗剂skerostin(SCL)的SOST基因是首要的,因为它在骨形成中的中心生物学作用,它在疾病中的影响,以及它作为潜在的治疗靶点的相关性。在理解SOST调控方面已经取得了进展,部分原因是发现下游的SOST增强子的缺失改变了SOST的表达,并导致了Van Bucem病。然而,我们的初步数据表明,复杂性显著增加,从而支持了这项提议的最终目标。目的:在体外和体内模型中,从表观基因组水平和调节基因组水平评估SOST基础和调控骨细胞表达的分子机制。骨细胞在骨骼中扮演着独特的角色,并以内分泌方式发挥作用,阐述局部旁分泌因子(如硬化素)和系统活性激素(如FGF23)。骨细胞功能异常引起的病理后果可能是灾难性的。从拟议的研究中得出的详细的基本见解可能会为多种疾病的治疗干预提供新的途径。 这会影响到骨骼。
英文摘要
DESCRIPTION (provided by applicant): Osteocytes are osteoblast-derived cells that are progressively entombed in mineralized matrix where they function to regulate skeletal homeostasis; their importance is highlighted both by their relative abundance and by their exceptionally long lifespan. Surprisingly, although osteocytes are known to manifest unique gene expression patterns relative to their osteoblast precursors and, as a consequence, display unique form and function, little is known of the molecular mechanisms that orchestrate their transition from the osteoblast or of the epigenomic and regulomic determinants that are responsible. In addition, although Wnt signaling is known to be a major but differential regulator of osteoblast and osteocyte activities, the majority of the gene targets that comprise the cell-specific activities of this pathway and the mechanisms through which TCF/LEF/b-catenin function to modulate these targets in both cell types remain unknown. Accordingly, the objectives of the first two aims are as follows. Aim 1: Identify the underlying epigenomic and regulomic mechanisms and associated molecular determinants that are responsible on a genome-wide scale for the osteoblast to osteocyte transition both in vitro and ex vivo. Aim 2: Examine and contrast the impact of the Wnt signaling pathway on osteoblast- and mature osteocyte-specific gene expression patterns and assess the molecular mechanisms through which these gene subsets are modulated directly by b-catenin and impacted by PTH and 1,25(OH)2D3 both in vitro and ex vivo. Our preliminary data and that of others have shown that a number of genes are upregulated during the osteocyte transition, including Sost, Fgf23, Tnfsf11, and Enpp1/3. The Sost gene, which encodes the Wnt pathway antagonist sclerostin (SCL), is of primary importance, however, due to its central biological actions on bone formation, its impact in disease, and its relevance as a potential therapeutic target. Progress has been made in understanding Sost regulation, prompted in part by the discovery that deletion of a downstream Sost enhancer alters Sost expression and is responsible for Van Buchem disease. Our preliminary data, however, suggest significant additional complexity, thus supporting the final objective of this proposal. Aim 3: Assess the molecular mechanisms that underlie both basal and regulated osteocyte expression of Sost at both epigenomic and regulomic levels in both in vitro and in vivo models. Osteocytes play unique roles in the skeleton and act in endocrine fashion to elaborate both local paracrine factors such as sclerostin and systemically active hormones such as FGF23. Pathologic consequences arising from aberrant osteocyte function can be catastrophic. Detailed basic insights arising from the proposed studies are likely to provide new routes of therapeutic intervention for a multiplicity of diseases that affect the skeleton.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transcriptional Control of Mouse FGF23 Expression in Health and Disease
  • 批准号:
    9904622
  • 项目类别:
  • 资助金额:
    $23.25万
  • 财政年份:
    2019
  • 负责人:
    J WESLEY PIKE
  • 依托单位:
Regulatory Mechanisms of Renal Vitamin D Activation and Degradation
  • 批准号:
    9888365
  • 项目类别:
  • 资助金额:
    $39.82万
  • 财政年份:
    2018
  • 负责人:
    J WESLEY PIKE
  • 依托单位:
Regulatory Mechanisms of Renal Vitamin D Activation and Degradation
  • 批准号:
    10373006
  • 项目类别:
  • 资助金额:
    $39.27万
  • 财政年份:
    2018
  • 负责人:
    J WESLEY PIKE
  • 依托单位:
Integrative genomics to define osteocyte differentiation, regulation and function
  • 批准号:
    8909062
  • 项目类别:
  • 资助金额:
    $34.0万
  • 财政年份:
    2014
  • 负责人:
    J WESLEY PIKE
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: